MedTrace Logo

Targeting Stress Reactivity in Schizophrenia: Integrated Coping Awareness Therapy

NCT03067311 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 38

Last updated 2021-03-03

Study results available
· View outcomes & findings →

Summary

To test the feasibility of a clinical trial implementing I-CAT, a novel therapeutic intervention combining strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life) for 40 people with first episode psychosis in the context of a small randomized controlled trial.

Conditions

  • Schizophreniform Disorders

Interventions

BEHAVIORAL

I-CAT

I-CAT is a novel therapeutic intervention combining mindfulness and meditation strategies to improve stress reactivity and increase meaningful coping, as well as a range of possible proximal (e.g. autonomic, endocrine, immune indices of stress reactivity, symptom severity) and distal measures (function, relapse, quality of life).

BEHAVIORAL

Treatment as Usual

Treatment as usual defined by participant clinician at OASIS clinic.

Sponsors & Collaborators

  • National Institute of Mental Health (NIMH)

    collaborator NIH

  • University of North Carolina, Chapel Hill

    lead OTHER

Principal Investigators

  • David L Penn, PhD · The Unviersity of North Carolina at Chapel Hill

  • Diana Perkins, MD · The Unviersity of North Carolina at Chapel Hill

  • Piper S Meyer-Kalos, PhD · Minnesota Center for Chemical and Mental Health

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
SINGLE
Model
PARALLEL

Eligibility

Min Age
15 Years
Max Age
35 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2016-10-03
Primary Completion
2020-03-30
Completion
2020-03-30

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03067311 on ClinicalTrials.gov